The Renin-angiotensin-aldosterone System and Its Suppression

Overview

Journal J Vet Intern Med

Specialties General Medicine
Veterinary Medicine

Date 2019 Feb 27

PMID 30806496

Citations 169

Authors

Marisa K Ames

Clarke E Atkins

Bertram Pitt

Affiliations

Soon will be listed here.

Abstract

Chronic activation of the renin-angiotensin-aldosterone system (RAAS) promotes and perpetuates the syndromes of congestive heart failure, systemic hypertension, and chronic kidney disease. Excessive circulating and tissue angiotensin II (AngII) and aldosterone levels lead to a pro-fibrotic, -inflammatory, and -hypertrophic milieu that causes remodeling and dysfunction in cardiovascular and renal tissues. Understanding of the role of the RAAS in this abnormal pathologic remodeling has grown over the past few decades and numerous medical therapies aimed at suppressing the RAAS have been developed. Despite this, morbidity from these diseases remains high. Continued investigation into the complexities of the RAAS should help clinicians modulate (suppress or enhance) components of this system and improve quality of life and survival. This review focuses on updates in our understanding of the RAAS and the pathophysiology of AngII and aldosterone excess, reviewing what is known about its suppression in cardiovascular and renal diseases, especially in the cat and dog.

Citing Articles

The Role of Reductive Stress in the Pathogenesis of Endocrine-Related Metabolic Diseases and Cancer.

Mladenov M, Sazdova I, Hadzi-Petrushev N, Konakchieva R, Gagov H Int J Mol Sci. 2025; 26(5).

PMID: 40076537 PMC: 11899626. DOI: 10.3390/ijms26051910.

A comprehensive review on cardiovascular disorders development due to salt intake: an emphasis on policy implementation.

Osoro I, Rajanandh M Health Res Policy Syst. 2025; 23(1):32.

PMID: 40069764 PMC: 11900108. DOI: 10.1186/s12961-025-01305-z.

Renin-Angiotensin-Aldosterone System Profiling in Horses Before and After Exercise.

Holbrook T, Hernandez J, McCarrel T, Lester G, Sleeper M, Domenig O J Vet Intern Med. 2025; 39(2):e70036.

PMID: 40048547 PMC: 11884522. DOI: 10.1111/jvim.70036.

Diagnosis and Management of Hypertensive Heart Disease: Incorporating 2023 European Society of Hypertension and 2024 European Society of Cardiology Guideline Updates.

Wang B J Cardiovasc Dev Dis. 2025; 12(2).

PMID: 39997480 PMC: 11856785. DOI: 10.3390/jcdd12020046.

Association between serum creatinine-to-albumin ratio and 28-day mortality in intensive care unit patients following cardiac surgery: analysis of mimic-iv data.

Shi P, Rui S, Meng Q BMC Cardiovasc Disord. 2025; 25(1):100.

PMID: 39953440 PMC: 11827414. DOI: 10.1186/s12872-025-04505-1.

References

Mosenkis A, Townsend R . Gynecomastia and antihypertensive therapy. J Clin Hypertens (Greenwich). 2004; 6(8):469-70. PMC: 8109613. DOI: 10.1111/j.1524-6175.2004.3735.x. View

Mochel J, Fink M, Bon C, Peyrou M, Bieth B, Desevaux C . Influence of feeding schedules on the chronobiology of renin activity, urinary electrolytes and blood pressure in dogs. Chronobiol Int. 2014; 31(5):715-30. DOI: 10.3109/07420528.2014.897711. View

Zheng J, Wei C, Hase N, Shi K, Killingsworth C, Litovsky S . Chymase mediates injury and mitochondrial damage in cardiomyocytes during acute ischemia/reperfusion in the dog. PLoS One. 2014; 9(4):e94732. PMC: 3986229. DOI: 10.1371/journal.pone.0094732. View

Ortega T, Feldman E, Nelson R, Willits N, Cowgill L . Systemic arterial blood pressure and urine protein/creatinine ratio in dogs with hyperadrenocorticism. J Am Vet Med Assoc. 1996; 209(10):1724-9. View

Brilla C, Rupp H, Funck R, Maisch B . The renin-angiotensin-aldosterone system and myocardial collagen matrix remodelling in congestive heart failure. Eur Heart J. 1995; 16 Suppl O:107-9. DOI: 10.1093/eurheartj/16.suppl_o.107. View

Geng D, Sun W, Yang L, En G, Wang J . Antiproteinuric effect of angiotensin receptor blockers in normotensive patients with proteinuria: a meta-analysis of randomized controlled trials. J Renin Angiotensin Aldosterone Syst. 2013; 15(1):44-51. DOI: 10.1177/1470320312474054. View

Atkins C, Keene B, Brown W, Coats J, Crawford M, DeFrancesco T . Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency. J Am Vet Med Assoc. 2007; 231(7):1061-9. DOI: 10.2460/javma.231.7.1061. View

DellItalia L, Balcells E, Meng Q, Su X, Schultz D, Bishop S . Volume-overload cardiac hypertrophy is unaffected by ACE inhibitor treatment in dogs. Am J Physiol. 1997; 273(2 Pt 2):H961-70. DOI: 10.1152/ajpheart.1997.273.2.H961. View

Flores-Munoz M, Smith N, Haggerty C, Milligan G, Nicklin S . Angiotensin1-9 antagonises pro-hypertrophic signalling in cardiomyocytes via the angiotensin type 2 receptor. J Physiol. 2010; 589(Pt 4):939-51. PMC: 3060371. DOI: 10.1113/jphysiol.2010.203075. View

10.

GUYTON A, Coleman T, Cowley Jr A, Liard J, Norman Jr R, Manning Jr R . Systems analysis of arterial pressure regulation and hypertension. Ann Biomed Eng. 1972; 1(2):254-81. DOI: 10.1007/BF02584211. View

11.

Girerd N, Pang P, Swedberg K, Fought A, Kwasny M, Subacius H . Serum aldosterone is associated with mortality and re-hospitalization in patients with reduced ejection fraction hospitalized for acute heart failure: analysis from the EVEREST trial. Eur J Heart Fail. 2013; 15(11):1228-35. DOI: 10.1093/eurjhf/hft100. View

12.

Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer J . Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest. 2002; 109(11):1417-27. PMC: 150992. DOI: 10.1172/JCI14276. View

13.

GUYTON A . Long-term arterial pressure control: an analysis from animal experiments and computer and graphic models. Am J Physiol. 1990; 259(5 Pt 2):R865-77. DOI: 10.1152/ajpregu.1990.259.5.R865. View

14.

Atkins C, Bonagura J, Ettinger S, Fox P, Gordon S, Haggstrom J . Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med. 2009; 23(6):1142-50. DOI: 10.1111/j.1939-1676.2009.0392.x. View

15.

Harada K, Izawa H, Nishizawa T, Hirashiki A, Murase Y, Kobayashi M . Beneficial effects of torasemide on systolic wall stress and sympathetic nervous activity in asymptomatic or mildly symptomatic patients with heart failure: comparison with azosemide. J Cardiovasc Pharmacol. 2009; 53(6):468-73. DOI: 10.1097/FJC.0b013e3181a717f7. View

16.

Pitt B, Pfeffer M, Assmann S, Boineau R, Anand I, Claggett B . Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014; 370(15):1383-92. DOI: 10.1056/NEJMoa1313731. View

17.

Ikeda U, Kanbe T, Nakayama I, Kawahara Y, Yokoyama M, Shimada K . Aldosterone inhibits nitric oxide synthesis in rat vascular smooth muscle cells induced by interleukin-1 beta. Eur J Pharmacol. 1995; 290(2):69-73. DOI: 10.1016/0922-4106(95)90018-7. View

18.

Lantis A, Ames M, Atkins C, DeFrancesco T, Keene B, Werre S . Aldosterone breakthrough with benazepril in furosemide-activated renin-angiotensin-aldosterone system in normal dogs. J Vet Pharmacol Ther. 2014; 38(1):65-73. DOI: 10.1111/jvp.12154. View

19.

Takeda Y, Miyamori I, Yoneda T, Iki K, Hatakeyama H, Blair I . Production of aldosterone in isolated rat blood vessels. Hypertension. 1995; 25(2):170-3. DOI: 10.1161/01.hyp.25.2.170. View

20.

Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S . Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation. 2004; 109(10):1284-91. PMC: 2779533. DOI: 10.1161/01.CIR.0000121426.43044.2B. View